Astec Lifesciences Ltd

Astec Lifescienc Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Astec Lifesciences Ltd

₹ 1,242 -1.52%
19 Apr - close price
astecls.com BSE: 533138 NSE : ASTEC
About

The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.
Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).[1] [2] [3]

Key Points

Product Portfolio
The company offers a range of products and intermediates, including fungicides, insecticides, herbicides, and various chemical compounds, serving global customers and including triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, fluorinated compounds, halides, intermediates, ketones, ethers, alcohols, and many others. [1]

Website BSE NSE
  • Market Cap ₹ 2,436 Cr.
  • Current Price ₹ 1,242
  • High / Low ₹ 1,542 / 825
  • Stock P/E
  • Book Value ₹ 201
  • Dividend Yield 0.12 %
  • ROCE 7.82 %
  • ROE 6.36 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Debtor days have improved from 120 to 90.0 days.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
116 172 129 103 173 272 184 200 117 127 143 111 51
100 134 104 81 130 207 159 166 105 122 140 114 69
Operating Profit 16 38 25 21 43 65 25 33 12 5 3 -3 -18
OPM % 13% 22% 19% 21% 25% 24% 14% 17% 10% 4% 2% -3% -36%
3 2 1 1 2 7 3 4 4 3 2 1 1
Interest 1 1 2 2 3 3 4 5 6 6 6 6 6
Depreciation 7 7 7 8 9 11 9 8 9 8 9 9 9
Profit before tax 11 32 17 12 33 58 15 25 1 -6 -11 -18 -32
Tax % 37% 26% 26% 25% 25% 26% 26% 25% 31% 19% 26% 24% 24%
7 24 13 9 25 43 11 18 1 -5 -8 -13 -24
EPS in Rs 3.60 12.22 6.62 4.63 12.63 21.96 5.81 9.33 0.42 -2.55 -4.19 -6.86 -12.42
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
110 165 189 252 221 298 368 431 522 555 677 628 431
94 138 155 200 190 236 299 354 437 443 522 551 445
Operating Profit 16 27 34 52 31 63 69 76 85 112 154 77 -13
OPM % 15% 16% 18% 21% 14% 21% 19% 18% 16% 20% 23% 12% -3%
1 0 0 -15 -0 -8 12 11 12 8 10 13 6
Interest 5 7 9 12 12 12 11 12 13 5 9 21 25
Depreciation 8 12 14 12 10 14 15 19 23 26 34 34 35
Profit before tax 3 9 11 12 8 29 56 56 61 89 121 35 -67
Tax % 30% 32% 22% -18% 95% 33% 37% 36% 23% 27% 26% 27%
2 6 9 15 0 19 35 36 47 65 90 26 -51
EPS in Rs 1.43 3.29 4.65 7.59 0.18 9.78 17.91 18.25 24.26 33.03 45.83 13.02 -26.02
Dividend Payout % 35% 23% 22% 16% -0% 15% 8% 8% 6% 5% 3% 12%
Compounded Sales Growth
10 Years: 14%
5 Years: 11%
3 Years: 6%
TTM: -44%
Compounded Profit Growth
10 Years: 15%
5 Years: -4%
3 Years: -18%
TTM: -169%
Stock Price CAGR
10 Years: 39%
5 Years: 19%
3 Years: 6%
1 Year: -10%
Return on Equity
10 Years: 17%
5 Years: 18%
3 Years: 17%
Last Year: 6%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 17 18 19 19 19 20 20 20 20 20 20 20 20
Reserves 81 89 96 117 99 118 150 183 227 289 376 399 375
70 70 79 93 127 127 125 176 99 188 280 341 432
58 81 85 128 84 69 119 83 227 182 221 219 83
Total Liabilities 227 258 279 358 329 334 413 461 572 678 897 979 909
76 120 130 127 94 103 115 167 194 213 340 318 407
CWIP 44 13 6 12 20 8 42 19 24 116 23 127 128
Investments 13 1 1 1 0 0 0 0 0 0 0 0 0
95 124 142 217 214 223 256 275 354 349 534 533 373
Total Assets 227 258 279 358 329 334 413 461 572 678 897 979 909

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
10 15 14 3 3 19 65 15 169 -8 23 74
-50 -13 -16 -14 -16 -18 -49 -52 -74 -73 -104 -112
40 -1 2 11 15 -1 -18 37 -95 81 80 38
Net Cash Flow 1 1 -0 -0 2 1 -2 -0 0 0 0 -0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 102 133 86 143 132 136 122 103 112 123 148 90
Inventory Days 206 133 187 143 186 133 122 121 131 113 176 268
Days Payable 140 137 120 181 179 117 156 83 219 137 180 161
Cash Conversion Cycle 167 129 153 105 140 152 88 141 24 99 145 197
Working Capital Days 175 126 135 122 150 155 115 147 77 101 163 175
ROCE % 6% 9% 11% 20% 10% 20% 22% 20% 20% 22% 22% 8%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
65.20% 65.20% 65.19% 65.29% 65.29% 66.77% 66.76% 66.76% 66.76% 66.75% 66.75% 66.75%
0.19% 0.22% 0.29% 0.32% 0.48% 1.53% 2.19% 2.29% 1.95% 1.33% 1.28% 1.25%
10.93% 12.21% 12.74% 12.56% 11.79% 9.82% 9.57% 10.58% 10.15% 10.16% 9.74% 7.88%
23.68% 22.37% 21.78% 21.83% 22.45% 21.87% 21.49% 20.37% 21.13% 21.74% 22.22% 24.12%
No. of Shareholders 22,81721,07319,00216,95117,43317,63219,54517,80918,70318,72219,24419,848

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls